Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide

Marielle M. Beckers; Gerwin Huls

doi:10.1111/ejh.12053

Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide

Marielle M. Beckers^*, Gerwin Huls

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

The prognosis of therapy refractory angioimmunoblastic lymphoma (AITL) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy. He was treated with lenalidomide 15 mg continuously and prednisone. After 2 yr follow-up, the patient has no detectable disease. Lenalidomide was well tolerated without side-effects. Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL.

Original language	English
Pages (from-to)	162-163
Number of pages	2
Journal	European Journal of Haematology
Volume	90
Issue number	2
DOIs	https://doi.org/10.1111/ejh.12053
Publication status	Published - Feb-2013

Keywords

angioimmunoblastic lymphoma
therapy refractory
lenalidomide

Access to Document

10.1111/ejh.12053

Handle.net

Persistent link

Cite this

@article{b178c159905e4803a62f2c2f737e53f6,

title = "Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide",

abstract = "The prognosis of therapy refractory angioimmunoblastic lymphoma (AITL) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy. He was treated with lenalidomide 15 mg continuously and prednisone. After 2 yr follow-up, the patient has no detectable disease. Lenalidomide was well tolerated without side-effects. Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL.",

keywords = "angioimmunoblastic lymphoma, therapy refractory, lenalidomide",

author = "Beckers, {Marielle M.} and Gerwin Huls",

year = "2013",

month = feb,

doi = "10.1111/ejh.12053",

language = "English",

volume = "90",

pages = "162--163",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley",

number = "2",

}

TY - JOUR

T1 - Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide

AU - Beckers, Marielle M.

AU - Huls, Gerwin

PY - 2013/2

Y1 - 2013/2

N2 - The prognosis of therapy refractory angioimmunoblastic lymphoma (AITL) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy. He was treated with lenalidomide 15 mg continuously and prednisone. After 2 yr follow-up, the patient has no detectable disease. Lenalidomide was well tolerated without side-effects. Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL.

AB - The prognosis of therapy refractory angioimmunoblastic lymphoma (AITL) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy. He was treated with lenalidomide 15 mg continuously and prednisone. After 2 yr follow-up, the patient has no detectable disease. Lenalidomide was well tolerated without side-effects. Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL.

KW - angioimmunoblastic lymphoma

KW - therapy refractory

KW - lenalidomide

U2 - 10.1111/ejh.12053

DO - 10.1111/ejh.12053

M3 - Article

SN - 0902-4441

VL - 90

SP - 162

EP - 163

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 2

ER -

Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this